ATE265207T1 - Verwendung von mehrfach ungesättigten fettsäuren zur vorbeugung von nekrotizierender enterokolitis - Google Patents

Verwendung von mehrfach ungesättigten fettsäuren zur vorbeugung von nekrotizierender enterokolitis

Info

Publication number: ATE265207T1
Authority: AT; Austria
Prior art keywords: fatty acids; polyunsaturated fatty; omega; pufas; necrotic enterocolitis
Prior art date: 1997-02-21

Application number

AT98906580T

Other languages

English (en)

Inventor

Susan E Carlson

Debra L Ponder

Michael B Montalto

Margaret H Dohnalek

John D Benson

David A Borror

David V Diodato

Original Assignee

Abbott Lab

Univ Tennessee Res Corportion

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-02-21

Filing date

1998-02-19

Publication date

2004-05-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27420004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE265207(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-10-03 Priority claimed from US08/943,576 external-priority patent/US6080787A/en

1998-02-19 Application filed by Abbott Lab, Univ Tennessee Res Corportion filed Critical Abbott Lab

2004-05-15 Application granted granted Critical

2004-05-15 Publication of ATE265207T1 publication Critical patent/ATE265207T1/de

Links

235000020777 polyunsaturated fatty acids Nutrition 0.000 title abstract 2
208000010227 enterocolitis Diseases 0.000 title 1
230000001338 necrotic effect Effects 0.000 title 1
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 abstract 4
235000021342 arachidonic acid Nutrition 0.000 abstract 2
229940114079 arachidonic acid Drugs 0.000 abstract 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 abstract 1
GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 abstract 1
102000002322 Egg Proteins Human genes 0.000 abstract 1
108010000912 Egg Proteins Proteins 0.000 abstract 1
206010051606 Necrotising colitis Diseases 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
235000020669 docosahexaenoic acid Nutrition 0.000 abstract 1
KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 abstract 1
235000013345 egg yolk Nutrition 0.000 abstract 1
210000002969 egg yolk Anatomy 0.000 abstract 1
150000002632 lipids Chemical class 0.000 abstract 1
235000020667 long-chain omega-3 fatty acid Nutrition 0.000 abstract 1
235000010598 long-chain omega-6 fatty acid Nutrition 0.000 abstract 1
235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
208000004995 necrotizing enterocolitis Diseases 0.000 abstract 1
201000006195 perinatal necrotizing enterocolitis Diseases 0.000 abstract 1
230000002195 synergetic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Fats And Perfumes (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Silicates, Zeolites, And Molecular Sieves (AREA)

AT98906580T 1997-02-21 1998-02-19 Verwendung von mehrfach ungesättigten fettsäuren zur vorbeugung von nekrotizierender enterokolitis ATE265207T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US80470097A	1997-02-21	1997-02-21
US82531497A	1997-03-28	1997-03-28
US08/943,576 US6080787A (en)	1997-02-21	1997-10-03	Methods for reducing the incidence of necrotizing enterocolitis
PCT/US1998/003235 WO1998036745A2 (en)	1997-02-21	1998-02-19	Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis

Publications (1)

Publication Number	Publication Date
ATE265207T1 true ATE265207T1 (de)	2004-05-15

Family

ID=27420004

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98906580T ATE265207T1 (de)	1997-02-21	1998-02-19	Verwendung von mehrfach ungesättigten fettsäuren zur vorbeugung von nekrotizierender enterokolitis

Country Status (23)

Country	Link
US (1)	US6306908B1 (de)
EP (1)	EP1039892B1 (de)
JP (1)	JP2001516343A (de)
CN (1)	CN1200701C (de)
AT (1)	ATE265207T1 (de)
AU (1)	AU732903B2 (de)
BR (1)	BR9807443A (de)
CA (1)	CA2281706C (de)
DE (1)	DE69823548T2 (de)
DK (1)	DK1039892T3 (de)
ES (1)	ES2219871T3 (de)
HU (1)	HUP0300236A3 (de)
ID (1)	ID22744A (de)
IL (1)	IL131126A (de)
NO (1)	NO994052L (de)
NZ (1)	NZ337039A (de)
PL (1)	PL343902A1 (de)
PT (1)	PT1039892E (de)
RU (1)	RU2199317C2 (de)
SK (1)	SK112399A3 (de)
TR (1)	TR199902023T2 (de)
TW (1)	TWI230607B (de)
WO (1)	WO1998036745A2 (de)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL121165A0 (en) *	1997-06-26	1997-11-20	Yissum Res Dev Co	Pharmaceutical compositions containing carboxylic acids and derivatives thereof
US6180671B1 (en) *	1998-03-10	2001-01-30	Beth Israel Deaconess Medical Center, Inc.	Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
DE19836339B4 (de) *	1998-08-11	2011-12-22	N.V. Nutricia	Kohlenhydratmischung
US20090274660A1 (en) *	1999-08-17	2009-11-05	Immunopath Profile, Inc.	Pluripotent therapeutic compositions and uses thereof
US6495599B2 (en) *	2000-04-13	2002-12-17	Abbott Laboratories	Infant formulas containing long-chain polyunsaturated fatty acids and uses therof
GB0016045D0 (en) *	2000-06-29	2000-08-23	Laxdale Limited	Therapeutic combinations of fatty acids
PT1542670E (pt) *	2002-09-24	2013-07-11	Suntory Holdings Ltd	Composição com efeitos na prevenção do declínio, melhoramento ou aumento de respostas normais de aptidões cognitivas de uma pessoa saudável
US7323206B1 (en)	2003-03-04	2008-01-29	B. Braun Medical Inc.	Reagents and methods for all-in-one total parenteral nutrition for neonates and infants
GB0311081D0 (en) *	2003-05-14	2003-06-18	Btg Internat Limted	Treatment of neurodegenerative conditions
PT1638414E (pt) *	2003-06-23	2009-07-13	Nestec Sa	Fórmula para lactentes ou fórmula de transição
CA2530170A1 (en) *	2003-06-24	2005-01-06	University Of Kansas Medical Center	Infant formula
GB2422373B (en)	2003-08-18	2008-05-21	Btg Int Ltd	Treatment of neurodegenerative conditions
EP1597978A1 (de)	2004-05-17	2005-11-23	Nutricia N.V.	Synergie von GOS und polyfruktose
US8252769B2 (en) *	2004-06-22	2012-08-28	N. V. Nutricia	Intestinal barrier integrity
EP1721611A1 (de) *	2005-04-21	2006-11-15	N.V. Nutricia	Nahrungsergänzungspräparat mit Oligosacchariden für eine Kategorie von HIV Patienten
SI1758469T2 (sl) *	2004-06-22	2013-12-31	N.V.Nutricia	IzboljĹˇanje integritete bariere pri HIV pacientih z uporabo maĹˇÄŤobnih kislin
US7862808B2 (en)	2004-07-01	2011-01-04	Mead Johnson Nutrition Company	Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
EP1656839A1 (de) *	2004-11-11	2006-05-17	N.V. Nutricia	Nahrung, die eine Lipidmischung enthält
GB0425932D0 (en) *	2004-11-25	2004-12-29	Btg Int Ltd	Structured phospholipids
GB0504362D0 (en) *	2005-03-02	2005-04-06	Btg Int Ltd	Cytokine modulators
GB0504333D0 (en) *	2005-03-02	2005-04-06	Btg Int Ltd	Treatment of cytokine dysregulation
US20060233762A1 (en) *	2005-04-15	2006-10-19	Mcmahon Robert J	Method for treating or preventing systemic inflammation in formula-fed infants
US7303745B2 (en)	2005-04-15	2007-12-04	Bristol-Myers Squibb Company	Method for preventing or treating the development of respiratory allergies
ATE471665T1 (de) *	2005-04-21	2010-07-15	Nutricia Nv	Nahrungsergänzungsmittel für hiv-patienten
DK2258219T4 (da) *	2005-04-27	2022-08-29	Nutricia Nv	Næring med lipider og ikke-fordøjelige saccharider
AU2006251562B2 (en)	2005-05-23	2012-03-22	Massachusetts Institute Of Technology	Compositions containing PUFA and methods of use thereof
JP2007063219A (ja) *	2005-09-01	2007-03-15	Juntendo	新生児壊死性腸炎疾患予防剤
EP1776877A1 (de) *	2005-10-21	2007-04-25	N.V. Nutricia	Methode zur Förderung der Darmflora
US20070166354A1 (en) *	2005-10-26	2007-07-19	Bridget Barrett-Reis	Method of reducing the risk of retinopathy of prematurity in preterm infants
US7829126B2 (en)	2005-10-26	2010-11-09	Abbott Laboratories	Infant formulas containing docosahexaenoic acid and lutein
US20070149617A1 (en)	2005-11-14	2007-06-28	Deckelbaum Richard J	Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs
BRPI0620465A2 (pt) *	2005-12-23	2011-11-16	Nutricia Nv	uso de uma composição
US20080003330A1 (en) *	2006-06-30	2008-01-03	Ricardo Rueda	Infant formulas for early brain development
US20080003329A1 (en) *	2006-06-30	2008-01-03	Ricardo Rueda	Enriched infant formulas
US7867542B2 (en) *	2006-11-02	2011-01-11	Ach Food Companies, Inc.	Non-flammable release composition
EP2200443B2 (de) *	2007-09-17	2021-06-30	Cornell University	Verzweigtkettige fettsäuren für die vorbeugung oder behandlung von störungen des magen-darm-trakts
BRPI0818079B8 (pt)	2007-10-09	2021-07-27	Enzymotec Ltd	composição de lipídeo
UY31410A1 (es) *	2007-10-30	2009-05-29		Composicion que comprende acidos grasos poliinsaturados y carbon vegetal activado
MX2010004820A (es)	2007-11-01	2010-08-10	Enzymotec Ltd	Mezcla lipidica para nutricion infantil.
MY168206A (en)	2007-12-20	2018-10-15	Abbott Lab	Stable nutritional powder
US8361534B2 (en) *	2007-12-20	2013-01-29	Abbott Laboratories	Stable nutritional powder
EP2100897A1 (de) *	2008-01-30	2009-09-16	BNLfood Investments SARL	Zusammensetzung auf Lecithinbasis und deren Verwendung in Nahrungsmitteln
WO2009096772A1 (en) *	2008-02-01	2009-08-06	N.V. Nutricia	Composition for stimulating natural killer cell activity
US9737213B1 (en) *	2009-03-24	2017-08-22	Vioptix, Inc.	Using an oximeter probe to detect intestinal ischemia
US9480670B2 (en) *	2009-04-01	2016-11-01	Nestec S.A.	Reduction of risk of obesity
TW201112967A (en)	2009-09-16	2011-04-16	Abbott Lab	Dryblended nutritional powders
TW201121431A (en) *	2009-12-01	2011-07-01	Abbott Lab	Soy protein-based nutritional formula with superior stability
TWI492744B (zh) *	2009-12-04	2015-07-21	Abbott Lab	使用類胡蘿蔔素調節早產兒發炎症之方法
CA2783768A1 (en) *	2009-12-08	2011-06-16	Nestec S.A.	Infant formula with probiotics and milk fat globule membrane components
CN102985105B (zh) *	2010-01-19	2016-03-09	雅培制药有限公司	包含合生元的营养配方
MX2012008785A (es)	2010-01-29	2012-08-17	Abbott Lab	Emulsiones nutricionales que comprenden beta-hidroxi-beta-metilbut irato (hmb) de calcio.
SG182808A1 (en)	2010-01-29	2012-09-27	Abbott Lab	Aseptically packaged nutritional liquids comprising hmb
US9693577B2 (en)	2010-01-29	2017-07-04	Abbott Laboratories	Method of preparing a nutritional powder comprising spray dried HMB
TWI526161B (zh)	2010-06-10	2016-03-21	亞培公司	包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
EP2397038A1 (de)	2010-06-21	2011-12-21	Abbott Laboratories	Frühe Programmierung der Hirnfunktion durch Sojaproteinzufuhr
WO2012009426A1 (en)	2010-07-13	2012-01-19	Abbott Laboratories	High tolerance infant formula including hydrolyzed protein
EP2422629A1 (de)	2010-08-23	2012-02-29	Abbott Laboratories	Verfahren zur Verbesserung der Kognition/von Gedächtnis mit Hilfe von Maltodextrin
ES2548629T3 (es)	2010-08-24	2015-10-19	Abbott Laboratories	Productos nutritivos que tienen propiedades organolépticas mejoradas
WO2012027287A1 (en)	2010-08-24	2012-03-01	Abbott Laboratories	Nutritional products including pea protein hydrolysates
ES2674430T3 (es) *	2010-12-29	2018-06-29	Abbott Laboratories	Producto nutricional para mejorar la tolerancia, digestión y absorción de nutrientes liposolubles en un lactante, niño pequeño o niño
ES2804258T3 (es)	2010-12-31	2021-02-05	Abbott Lab	Procedimientos para reducir la incidencia de estrés oxidativo usando oligosacáridos de leche humana, vitamina C y agentes antiinflamatorios
ES2667393T3 (es)	2010-12-31	2018-05-10	Abbott Laboratories	Oligosacáridos de leche humana para modular inflamación
WO2012092155A1 (en)	2010-12-31	2012-07-05	Abbott Laboratories	Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
US8802650B2 (en)	2010-12-31	2014-08-12	Abbott Laboratories	Methods of using human milk oligosaccharides for improving airway respiratory health
CA2822490C (en)	2010-12-31	2020-03-31	Abbott Laboratories	Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
CN107019701B (zh)	2010-12-31	2020-07-28	雅培制药有限公司	使用人乳低聚糖来降低婴儿、幼儿或儿童的坏死性小肠结肠炎的发病率的方法
MY166945A (en)	2010-12-31	2018-07-25	Abbott Lab	Nutritional formulations including human milk oligosaccharides and long chain polyunsaturated polyunsaturated fatty acids and uses thereof
MY191538A (en)	2010-12-31	2022-06-30	Abbott Lab	Human milk oligosaccharides to promote growth of beneficial bacteria
WO2013012989A2 (en)	2011-07-19	2013-01-24	The Trustees Of Columbia University In The City Of New York	Method and system for production of hydrogen and carbon monoxide
EP2734210B1 (de)	2011-07-22	2017-11-22	Abbott Laboratories	Galactooligosaccharide zur prävention von verletzungen und/oder förderung der heilung des magen-darm-traktes
CA2846603A1 (en)	2011-08-29	2013-03-07	Abbott Laboratories	Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
WO2013101516A1 (en)	2011-12-29	2013-07-04	Abbott Laboratories	Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using extracted genomic dna
MX2014008023A (es)	2011-12-29	2014-12-08	Abbott Lab	Metodos para reducir la contaminacion microbiana de composiciones nutritivas en polvo mezcladas en seco.
EP2830712A1 (de)	2012-03-27	2015-02-04	Abbott Laboratories	Verfahren zur modulierung von zellvermittelter immunität mit muttermilcholigosacchariden
WO2013170189A1 (en)	2012-05-11	2013-11-14	Abbott Laboratories	Combination of beta - hydroxy - beta - methylbutyrate and beta - alanine for increasing muscle blood flow
ES2572831T3 (es)	2012-09-14	2016-06-02	Abbott Laboratories	Composiciones nutricionales para su uso en métodos para modular los niveles de corticosterona en individuos con estrés psicológico
EP2708147B1 (de)	2012-09-14	2020-03-11	Abbott Laboratories	Verfahren zur Erhöhung der Gehirnfunktion unter Verwendung von 2-Fucosyl-Lactose
EP2708146A1 (de)	2012-09-17	2014-03-19	Abbott Laboratories, Inc.	Ernährungszusammensetzung für schwangere Frauen mit einem förderlichen Glucose- und Insulinprofil
WO2014078544A1 (en)	2012-11-14	2014-05-22	Abbott Laboratories	Compositions and methods for improving the long term safety of powdered infant formulas
WO2014099904A1 (en)	2012-12-17	2014-06-26	Abbott Laboratories	Methods for enhancing motor function, enhancing functional status and mitigating muscle weakness in a subject
EP2745705A1 (de)	2012-12-18	2014-06-25	Abbott Laboratories	Ernährungsbedingte Verwendung von Muttermilch Oligosacchariden
WO2014100022A1 (en)	2012-12-18	2014-06-26	Abbott Laboratories	Dietary oligosaccharides to enhance learning and memory
BR112015014420A2 (pt)	2012-12-18	2017-07-11	Abbott Lab	oligossacarídeos do leite humano para melhorar sintomas de estresse
TWI673052B (zh)	2012-12-20	2019-10-01	美商亞培公司	使用人乳寡糖之用於調節炎症之營養調配物
EP2745708A1 (de)	2012-12-24	2014-06-25	Abbott Laboratories, Inc.	Antidepressionswirkung von ß-Hydroxy-ß-Methylbutyrat
SG11201507198PA (en)	2013-03-12	2015-10-29	Abbott Lab	Composition comprising a multifunctional viscosity modifying agent
HK1221611A1 (zh)	2013-03-15	2017-06-09	Abbott Laboratories	维持和改善肌肉功能的方法
EP2986163B1 (de)	2013-03-15	2017-04-19	Abbott Laboratories	Nahrungsmittelprodukte mit calcium beta-hydroxy-beta-methylbutyrat, caseinphosphopeptide und proteine
CN105263321B (zh)	2013-03-28	2018-07-27	哥伦比亚大学纽约管理委员会	用omega-3甘油酯再灌注促进对用于移植的供体器官的保护
MX2015017056A (es)	2013-06-10	2016-04-13	Abbott Lab	Metodos y composiciones para incrementar el desempeño cognitivo.
WO2015048646A1 (en)	2013-09-30	2015-04-02	Abbott Laboratories	Protein powder
US20160213040A1 (en)	2013-10-11	2016-07-28	Abbott Laboratories	Nutritional composition for pregnant women with a beneficial glucose and insulin profile
CN103558296B (zh) *	2013-10-18	2015-03-04	中国农业大学	一种基于脂肪酸检测的动物源性饲料原料鉴别方法
CN104623637A (zh)	2013-11-07	2015-05-20	健能隆医药技术（上海）有限公司	Il-22二聚体在制备静脉注射药物中的应用
US10568896B2 (en)	2013-11-19	2020-02-25	Abbott Laboratories	Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides
EP2888950A1 (de)	2013-12-24	2015-07-01	Abbott Laboratories	Verfahren zur Behandlung, Prävention oder Verringerung von Nervenentzündung oder kognitiver Beeinträchtigung
WO2015105981A2 (en)	2014-01-09	2015-07-16	Abbott Laboratories	Conditional essentiality of hmb
SG11201608248YA (en)	2014-04-08	2016-10-28	Abbott Lab	Methods for enhancing mucosal innate immune responses to and/or detection of pathogens using human milk oligosaccharides
DE102015101273A1 (de) *	2015-01-29	2016-08-04	Eberhard Karls Universität Tübingen Medizinische Fakultät	Prophylaxe und Behandlung von frühgeburtlichkeitsassoziierten Entwicklungsstörungen
ES2930351T3 (es)	2016-04-15	2022-12-09	Evive Biotechnology Shanghai Ltd	Un dímero de IL-22 para su uso en el tratamiento de enterocolitis necrosante
RU2665947C1 (ru) *	2017-07-13	2018-09-05	Атикат Магомедхановна Герейханова	Способ лечения некротического энтероколита
CA3141763A1 (en)	2019-06-07	2020-12-10	Abbott Laboratories	Nutritional ingredient with flow and antifoam properties
WO2021164744A1 (en)	2020-02-19	2021-08-26	Evive Biotechnology (Shanghai) Ltd	Methods for treating graft versus host disease
JP2023520558A (ja)	2020-04-06	2023-05-17	アボット・ラボラトリーズ	呼吸器系誘導性サイトカインを調節する栄養処方剤
CN112137998A (zh) *	2020-10-10	2020-12-29	上海交通大学医学院附属新华医院	一种活性成分在制备防治坏死性小肠结肠炎药物中的应用
WO2022177965A1 (en)	2021-02-16	2022-08-25	Abbott Laboratories	Nutritional compositions comprising human milk oligosaccharides and bovine immunoglobulin
WO2022226311A1 (en)	2021-04-23	2022-10-27	Abbott Laboratories	Nutritional compositions comprising human milk oligosaccharides and a designed lipid component for improving lung function
WO2022266058A1 (en)	2021-06-14	2022-12-22	Abbott Laboratories	Methods and compositions for treating gas
WO2023159093A1 (en)	2022-02-16	2023-08-24	Abbott Laboratories	Nutritional compositions comprising human milk oligosaccharides and bovine immunoglobulin
WO2024064327A1 (en)	2022-09-22	2024-03-28	Abbott Laboratories	Human milk oligosaccharides for enhancing blood-brain barrier function

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0092121B1 (de)	1982-04-12	1987-12-16	Board Of Regents, The University Of Texas System	Verfahren und Zusammensetzungen zur Behandlung von Magen- und Darm-Ulcus
US4670285A (en)	1982-08-06	1987-06-02	The University Of Toronto Innovations Foundation	Infant formula
US4784861A (en)	1986-11-24	1988-11-15	Cca Industries, Inc.	Weight-control formulation
US5043329A (en)	1987-02-17	1991-08-27	Board Of Regents, University Of Texas System	Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US5032585A (en)	1987-02-17	1991-07-16	Board Of Regents, The University Of Texas System	Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy
US4918063A (en) *	1987-02-17	1990-04-17	Board Of Regents, The University Of Texas System	Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US4950656A (en)	1987-02-17	1990-08-21	Board Of Regents, The University Of Texas System	Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US5000975A (en)	1988-12-29	1991-03-19	American Home Products Corporation	Randomized palm oil fat composition for infant formulas
US5116819A (en) *	1989-05-05	1992-05-26	Clintec Nutrition Co.	Enteral diet for patients with pulmonary disease
US5658767A (en)	1991-01-24	1997-08-19	Martek Corporation	Arachidonic acid and methods for the production and use thereof
ES2157898T3 (es)	1991-01-24	2001-09-01	Martek Corp	Aceites microbianos y usos de los mismos.
WO1993020717A2 (en) *	1992-04-13	1993-10-28	Research Corporation Technologies, Inc.	Reducing gastrointestinal irritation in infant nutrition
DE4407939A1 (de) *	1993-03-15	1994-09-22	Sueddeutsche Kalkstickstoff	Verfahren zur Herstellung von fett- und cholesterinreduzierten pulverförmigen Produkten auf Eibasis
FR2721481B1 (fr) *	1994-06-27	1996-09-06	Inst Rech Biolog Sa	Nouvelles compositions diététiques à base de phospholipides et leur utilisation comme complément nutritionnel.
ATE167983T1 (de)	1994-10-05	1998-07-15	Milupa Gmbh & Co Kg	Phospholipidhaltige fettmischung mit lcp- fettsäuren
JPH09201A (ja) *	1995-06-23	1997-01-07	Akikuni Yakida	炎症性腸疾患用食品
US5917068A (en)	1995-12-29	1999-06-29	Eastman Chemical Company	Polyunsaturated fatty acid and fatty acid ester mixtures free of sterols and phosphorus compounds
US5790138A (en)	1996-01-16	1998-08-04	Monolithic System Technology, Inc.	Method and structure for improving display data bandwidth in a unified memory architecture system

1998
- 1998-02-19 HU HU0300236A patent/HUP0300236A3/hu unknown
- 1998-02-19 CA CA002281706A patent/CA2281706C/en not_active Expired - Fee Related
- 1998-02-19 AT AT98906580T patent/ATE265207T1/de not_active IP Right Cessation
- 1998-02-19 WO PCT/US1998/003235 patent/WO1998036745A2/en not_active Ceased
- 1998-02-19 CN CNB988043726A patent/CN1200701C/zh not_active Expired - Fee Related
- 1998-02-19 PL PL98343902A patent/PL343902A1/xx unknown
- 1998-02-19 RU RU99119892/14A patent/RU2199317C2/ru not_active IP Right Cessation
- 1998-02-19 TR TR1999/02023T patent/TR199902023T2/xx unknown
- 1998-02-19 SK SK1123-99A patent/SK112399A3/sk unknown
- 1998-02-19 DK DK98906580T patent/DK1039892T3/da active
- 1998-02-19 ES ES98906580T patent/ES2219871T3/es not_active Expired - Lifetime
- 1998-02-19 PT PT98906580T patent/PT1039892E/pt unknown
- 1998-02-19 JP JP53687198A patent/JP2001516343A/ja active Pending
- 1998-02-19 NZ NZ337039A patent/NZ337039A/en unknown
- 1998-02-19 AU AU61769/98A patent/AU732903B2/en not_active Ceased
- 1998-02-19 EP EP98906580A patent/EP1039892B1/de not_active Revoked
- 1998-02-19 IL IL13112698A patent/IL131126A/xx not_active IP Right Cessation
- 1998-02-19 BR BR9807443-1A patent/BR9807443A/pt not_active IP Right Cessation
- 1998-02-19 DE DE69823548T patent/DE69823548T2/de not_active Revoked
- 1998-02-19 ID IDW990897A patent/ID22744A/id unknown
- 1998-04-03 TW TW087102492A patent/TWI230607B/zh not_active IP Right Cessation
1999
- 1999-08-23 NO NO994052A patent/NO994052L/no not_active Application Discontinuation
2000
- 2000-05-12 US US09/570,299 patent/US6306908B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP2001516343A (ja)	2001-09-25
CN1200701C (zh)	2005-05-11
CA2281706A1 (en)	1998-08-27
IL131126A (en)	2003-04-10
CA2281706C (en)	2008-08-05
HUP0300236A3 (en)	2003-09-29
SK112399A3 (en)	2000-12-11
TWI230607B (en)	2005-04-11
NO994052L (no)	1999-10-20
NO994052D0 (no)	1999-08-23
DE69823548T2 (de)	2005-02-24
PT1039892E (pt)	2004-09-30
ID22744A (id)	1999-12-09
BR9807443A (pt)	2000-04-25
ES2219871T3 (es)	2004-12-01
HK1034033A1 (en)	2001-10-12
NZ337039A (en)	2001-06-29
WO1998036745A3 (en)	2002-10-03
TR199902023T2 (xx)	2001-09-21
WO1998036745A2 (en)	1998-08-27
CN1269718A (zh)	2000-10-11
IL131126A0 (en)	2001-01-28
AU6176998A (en)	1998-09-09
EP1039892A2 (de)	2000-10-04
DK1039892T3 (da)	2004-08-30
PL343902A1 (en)	2001-09-10
HUP0300236A2 (hu)	2003-06-28
AU732903B2 (en)	2001-05-03
US6306908B1 (en)	2001-10-23
RU2199317C2 (ru)	2003-02-27
DE69823548D1 (de)	2004-06-03
EP1039892B1 (de)	2004-04-28

Legal Events

Date

Code

Title

Description

2005-01-15

UEP

Publication of translation of european patent specification

Ref document number: 1039892

Country of ref document: EP

2007-08-15

RZN

Patent revoked

Publication	Publication Date	Title
DE69823548D1 (de)	2004-06-03	Verwendung von mehrfach ungesättigten fettsäuren zur vorbeugung von nekrotizierender enterokolitis
Vidgren et al.	1997	Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men
AR005556A1 (es)	1999-06-23	Formula enteral, un suplemento nutricional que contiene una composicion de trigliceridos, trigliceridos, y un procedimiento para preparar esteres de acidos grasos a partir de una mezcla de lipidos
DE69622722D1 (de)	2002-09-05	Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselssyndroms
DK1121115T3 (da)	2007-07-02	PUFA-tilskud
PL190841B1 (pl)	2006-02-28	Syntetyczna kompozycja lipidowa i jej zastosowanie do wytwarzania pokarmu dla niemowląt
EP2255668A3 (de)	2012-04-04	Herstellung und Verwendung einer an polaren Lipiden reichen Fraktion, die hoch ungesättigte Omega-3- und/oder Omega-6-Fettsäuren aus Mikroben, Samen genetisch modifizierter Pflanzen und marinen Organismen enthält
US20140275483A1 (en)	2014-09-18	Algal oil compositions
MX2008014264A (es)	2009-05-20	Esteres de glicerol estructurados utiles como barreras de humedad comestibles.
JP2021137035A5 (ja)	2021-12-02	高度不飽和脂肪酸のトリグリセリドを含む組成物
DK1027831T3 (da)	2006-02-20	Stabiliseret fedtstofsammensætning, fremgangsmåde til fremstilling deraf og ernæringsprodukt indeholdende denne
ATE454820T1 (de)	2010-01-15	Neuartige fettpulver
Yeo et al.	2000	Plasma phospholipids, including plasmalogens, after consumption of diets enriched in long-chain n-3 fatty acids
OGUNLEIYE et al.	1990	Effect of fish oil and safflower oil in common Japanese diet on human plasma fatty acid composition
Sandoval et al.	2017	Omega-3 in the Prevention of Cardiovascular Diseases
Ouyang et al.	2016	Resources and bioactivities of polyunsaturated fatty acids
Wallace	2000	Dietary fatty acids affect inflammatory mediator production by mirine and human macrophages and lymphocytes
Šimat et al.	2014	Amounts of n-3 and n-6 fatty acids, fatty acids profile and nutritive value of canned sardines in different coating media
van den Elsen et al.	2013	TWO